A Phase 2 interventional study of Ramucirumab (IMC-1121B) in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-08.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 8th largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 2, and was the 2nd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 2
First in 2008; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 47 across the 13 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
Inhibition of angiogenesis is considered a promising approach to the treatment of cancer. Members of the vascular endothelial growth factor (VEGF) family and the VEGF receptor-2 (VEGFR-2) are important mediators of angiogenesis and are likely important therapeutic targets in advanced hepatocellular cancer (HCC).
Angiogenesis appears integral to HCC development and pathogenesis. Angiogenesis inhibition has been efficacious in both in vitro and in vivo HCC models and results of clinical studies also suggest potential to inhibit disease growth.
Ramucirumab is a fully human monoclonal antibody (MAb) that specifically binds to the extracellular domain of VEGFR-2 with high affinity. Phase 1 studies currently nearing completion have demonstrated safety and tolerability at clinically relevant doses, with preliminary evidence of clinical efficacy in a variety of human cancers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ramucirumab (IMC-1121B)
Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
Also known as: Ramucirumab, IMC-1121B, LY3009806
Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab
PFS was defined as the time from the first day of therapy to the first evidence of disease progression or death from any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Participants who were alive and without disease progression and participants who did not progress and were subsequently lost to follow-up were censored at the last objective tumor assessment.
Time frame: First dose to date of progressive disease or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)]
Time to Progression
The time from first day of therapy to the first date of objective evidence of progressive disease (PD) by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of new lesion. Time to PD was censored at the date of death or study discontinuation.
Time frame: First dose to date of PD [every 3 cycles up to 18 months (1 cycle=2 weeks)]
Overall Survival
Overall survival (OS) was the duration from first dose to death due to any cause. OS was censored at last contact date for participants who were alive at the end of follow-up period or lost to follow-up.
Time frame: First dose to death due to any cause up to 37.5 months
Percentage of Participants With Complete Response or Partial Response (Objective Response Rate)
Objective response rate (ORR) was defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). As classified according to Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) and normalization of tumor marker level of non-target lesions. PR was having at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: First dose to date of objective progressive disease (PD) or death up to 18 months
Duration of Response
Duration of response was the interval from the date of initial documented response \[complete response (CR) or partial response (PR)\] to the first documented date of disease progression, initiation of other (or additional) antitumor therapy was first reported, or death due to any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target lesions, PR was having at least a 30% decrease in the sum of the longest diameter of target lesions, and disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data were censored for participants who did not progress or die.
Time frame: Time of first response (CR or PR) to disease progression, or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)]
Number of Participants With Serum Anti-Ramucirumab Antibodies
Time frame: Prior to dosing at baseline, Cycles 4 and 7, and 30 days after end of therapy (1 cycle=2 weeks)
Number of Participants With Drug-Related Treatment-Emergent Adverse Events
Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered by the investigator to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: First dose to 37.5 months
| Milestone | Ramucirumab (IMC-1121B) |
|---|---|
| Started | 42 |
| Received at least 1 dose of study drug | 42 |
| Completed | 40 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
PFS was defined as the time from the first day of therapy to the first evidence of disease progression or death from any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Participants who were alive and without disease progression and participants who did not progress and were subsequently lost to follow-up were censored at the last objective tumor assessment.
| months | Ramucirumab (IMC-1121B) |
|---|---|
| Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab | 4.0 (2.6 to 5.7) |
The time from first day of therapy to the first date of objective evidence of progressive disease (PD) by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of new lesion. Time to PD was censored at the date of death or study discontinuation.
| months | Ramucirumab (IMC-1121B) |
|---|---|
| Time to Progression | 4.2 (2.8 to 8.4) |
Overall survival (OS) was the duration from first dose to death due to any cause. OS was censored at last contact date for participants who were alive at the end of follow-up period or lost to follow-up.
| months | Ramucirumab (IMC-1121B) |
|---|---|
| Overall Survival | 12.0 (6.1 to 19.7) |
Objective response rate (ORR) was defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). As classified according to Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) and normalization of tumor marker level of non-target lesions. PR was having at least a 30% decrease in sum of longest diameter of target lesions.
| percentage of participants | Ramucirumab (IMC-1121B) |
|---|---|
| Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) | 9.5 (2.7 to 22.6) |
Duration of response was the interval from the date of initial documented response \[complete response (CR) or partial response (PR)\] to the first documented date of disease progression, initiation of other (or additional) antitumor therapy was first reported, or death due to any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target lesions, PR was having at least a 30% decrease in the sum of the longest diameter of target lesions, and disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data were censored for participants who did not progress or die.
| months | Ramucirumab (IMC-1121B) |
|---|---|
| Duration of Response | 14.1 (4.3 to 14.1) |
| participants | Ramucirumab (IMC-1121B) |
|---|---|
| Number of Participants With Serum Anti-Ramucirumab Antibodies | 6 |
Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered by the investigator to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.
| participants | Ramucirumab (IMC-1121B) |
|---|---|
| Related TEAE | 41 |
| Related SAE | 9 |
| Related Grade 3 or higher TEAE | 14 |
| Related AE leading to discontinuation | 6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab (IMC-1121B) | — | 24/42 (57.1%) | 41/42 (97.6%) |
| Event | Ramucirumab (IMC-1121B) |
|---|---|
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 3/42 |
| HYPERTENSIONVascular disorders | 3/42 |
| ASCITESGastrointestinal disorders | 2/42 |
| FATIGUEGeneral disorders | 2/42 |
| INFUSION RELATED REACTIONGeneral disorders | 2/42 |
| PYREXIAGeneral disorders | 2/42 |
| PNEUMONIAInfections and infestations | 2/42 |
| CONFUSIONAL STATEPsychiatric disorders | 2/42 |
| HYPOXIARespiratory, thoracic and mediastinal disorders | 2/42 |
| ADRENAL INSUFFICIENCYEndocrine disorders | 1/42 |
| Event | Ramucirumab (IMC-1121B) |
|---|---|
| FATIGUEGeneral disorders | 28/42 |
| HEADACHENervous system disorders | 16/42 |
| HYPERTENSIONVascular disorders | 16/42 |
| NAUSEAGastrointestinal disorders | 15/42 |
| DIARRHOEAGastrointestinal disorders | 14/42 |
| OEDEMA PERIPHERALGeneral disorders | 14/42 |
| ANOREXIAMetabolism and nutrition disorders | 11/42 |
| ABDOMINAL DISTENSIONGastrointestinal disorders | 8/42 |
| ABDOMINAL PAINGastrointestinal disorders | 8/42 |
| WEIGHT DECREASEDInvestigations | 8/42 |
Participants who received at least 1 dose of ramucirumab.
| Age, Customized(participants) | Ramucirumab (IMC-1121B) |
|---|---|
| Between 18 and 65 years | 27 ± 10.70 |
| >=65 years | 15 |
| Sex: Female, Male(Participants) | Ramucirumab (IMC-1121B) |
|---|---|
| Female | 8 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab (IMC-1121B) |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 39 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(participants) | Ramucirumab (IMC-1121B) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 32 |
| Race Other: Hispanic | 1 |
| Race Other: Black and Asian | 1 |
| Race Other: Greek | 1 |
| Region of Enrollment(participants) | Ramucirumab (IMC-1121B) |
|---|---|
| United States | 42 |
| Child-Pugh Score(participants) | Ramucirumab (IMC-1121B) |
|---|---|
| A | 31 |
| B | 11 |
| Barcelona Stage(participants) | Ramucirumab (IMC-1121B) |
|---|---|
| A | 2 |
| B | 4 |
| C | 36 |
| Macrovascular Invasion(participants) | Ramucirumab (IMC-1121B) |
|---|---|
| Present | 7 |
| Absent | 32 |
| Not Available | 2 |
| Missing | 1 |
2 further baseline measures are reported on the registry.
The record gives a start of Feb 2008, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 3 years 2 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab